Sangui Biotech International, Inc. Announces Earnings Results for the First Quarter Ended September 30, 2018
November 15, 2018 at 04:13 am EST
Share
Sangui Biotech International, Inc. announced earnings results for the first quarter ended September 30, 2018. The company achieved revenues from royalty income of USD 11,272. In the same period of the previous year the comparable revenue amounted to USD 16,636. Due to decreased revenues of the wound spray Granulox, the resulting royalty income in the first three months decreased by 32% compared to the same period of the previous year. The operating loss for the first three months increased by USD 35,709 to USD 93,498 compared to the same period last year.
Sangui Biotech International, Inc. focuses on the development of pharmaceutical, medical and cosmetic products. The Company develops its products through its German subsidiary, SanguiBioTech AG (Sangui GmbH). It is engaged in seeking to market and selling its products through partnerships with industry partners across the world. It focuses on the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. It focuses its development and commercialization efforts on such artificial oxygen carriers by reproducing and synthesizing polymers out of native hemoglobin of defined molecular sizes. It offers external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays for the healing of chronic wounds and of gels and emulsions for the regeneration of the skin.
SANGUI BIOTECH INTERNATIONAL, INC. 
